Home › Cases › Malignancy-Related Hypercalcaemia
Hypercalcaemia
Malignancy-Related Hypercalcaemia
6 questions
Question 1 · Recognition
Correct answer: Moderate-severe hypercalcaemia — hospital admission and IV treatment
Why
Ca2+ 3.4 = moderate-severe hypercalcaemia (>3.0 symptomatic). Drowsiness + GI symptoms + malignancy background = requires urgent IV treatment.
Key point
Ca2+ >3.0 with symptoms: hospital treatment. Ca2+ >3.5: urgent correction even without confusion; confusion or arrhythmia increases urgency.
Question 2 · Mechanism
Correct answer: PTHrP (parathyroid hormone-related peptide) secretion by tumour + osteoclast activation from bone mets
Why
Malignancy-related hypercalcaemia: PTHrP from tumour (humoural) + direct osteoclast activation from bone mets. PTH will be suppressed (unlike primary hyperparathyroidism).
Key point
Malignancy: PTH is low/suppressed. PTHrP elevated. Unlike primary hyperparathyroidism (PTH high).
Question 3 · IV fluids
Correct answer: 0.9% NaCl 200-300ml/hr — rehydrate first and reassess frequently
Why
Rehydration is the first step in this volume-depleted patient. Hypercalcaemia can cause nephrogenic DI — polyuria worsens dehydration. Fluids also enhance calciuresis. Reassess lungs, fluid balance and renal function; reduce the rate if overload develops.
Key point
Rehydrate volume depletion first; target UO 100–150ml/hr with frequent reassessment. Start bisphosphonate once rehydration is established.
Question 4 · Bisphosphonate
Correct answer: Zoledronic acid 4mg IV over 15 minutes (after checking creatinine)
Why
- Zoledronic acid: most potent bisphosphonate, onset 24-48h, lasts 2-4 weeks.
- Check creatinine before.
- In tumour-induced hypercalcaemia the SmPC needs no dose adjustment below creatinine 400 µmol/L ; severe renal impairment needs specialist risk–benefit assessment.
- The CrCl <35 ml/min contraindication applies to Aclasta 5mg for osteoporosis/Paget’s, not this regimen.
- Furosemide historically used but now not recommended as first-line.
Key point
Bisphosphonate (zoledronic acid) for malignancy-related hypercalcaemia. Check renal function first.
Question 5 · Calcitonin
Correct answer: Calcitonin 4 IU/kg IM/SC — rapid onset (4-6h), good bridge to bisphosphonate
Why
Calcitonin 4 IU/kg IM/SC acts in 4–6 h but wears off (tachyphylaxis) — a bridge only, max 48–72 h. Arrange IV bisphosphonate the same day with senior/pharmacy help.
Key point
Calcitonin 4 IU/kg IM/SC: works in 4–6 h, max 48–72 h. Bridge to bisphosphonate.
Question 6 · Underlying disease
Correct answer: Oncology for systemic cancer treatment — treating hypercalcaemia without treating cancer is temporising
Why
Treating hypercalcaemia without addressing the malignancy is temporary. Oncology input for systemic treatment (chemotherapy, hormone therapy, targeted therapy) is the definitive management.
Key point
Hypercalcaemia of malignancy: treating the calcium is temporising. Oncology is definitive.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.